Alumis (ALMS) News Today $10.02 +1.48 (+17.33%) As of 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Alumis Inc. (NASDAQ:ALMS) CEO Acquires $100,786.00 in StockApril 4 at 5:52 AM | insidertrades.comHC Wainwright Weighs in on Alumis' Q1 Earnings (NASDAQ:ALMS)Alumis Inc. (NASDAQ:ALMS - Free Report) - Stock analysts at HC Wainwright boosted their Q1 2025 EPS estimates for shares of Alumis in a research report issued on Wednesday, March 26th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of ($1.07) per share for the quaMarch 29, 2025 | marketbeat.comHC Wainwright Forecasts Alumis' Q1 Earnings (NASDAQ:ALMS)March 29, 2025 | americanbankingnews.comQ2 Earnings Forecast for Alumis Issued By Leerink PartnrsMarch 28, 2025 | americanbankingnews.comAlumis (NASDAQ:ALMS) Receives "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $15.00 price target on shares of Alumis in a research note on Wednesday.March 27, 2025 | marketbeat.comLeerink Partnrs Predicts Alumis' Q2 Earnings (NASDAQ:ALMS)Alumis Inc. (NASDAQ:ALMS - Free Report) - Investment analysts at Leerink Partnrs issued their Q2 2025 earnings estimates for shares of Alumis in a research note issued to investors on Sunday, March 23rd. Leerink Partnrs analyst T. Smith anticipates that the company will post earnings per share ofMarch 27, 2025 | marketbeat.comAlumis, Kaken Pharmaceutical enter ESK-001 collaboration and licensing agreementMarch 27, 2025 | markets.businessinsider.comAlumis Inc. Reports 2024 Results and Strategic MergerMarch 27, 2025 | tipranks.comQ1 Earnings Estimate for Alumis Issued By Leerink PartnrsAlumis Inc. (NASDAQ:ALMS - Free Report) - Analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Alumis in a research note issued on Sunday, March 23rd. Leerink Partnrs analyst T. Smith expects that the company will post earnings per share of ($1.46) for the quarter. The conMarch 26, 2025 | marketbeat.comStrategic Partnerships and Financial Projections Bolster Buy Rating for Alumis Inc.March 26, 2025 | tipranks.comAlumis stock soars on Japan dermatology dealMarch 25, 2025 | investing.comAlumis rises on licensing deal with Japan’s KakenMarch 25, 2025 | msn.comPositive Buy Rating for Alumis Inc. Driven by Promising TYK2 Inhibitors and Strategic AdvancementsMarch 25, 2025 | tipranks.comAlumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in JapanMarch 25, 2025 | globenewswire.comFY2025 EPS Estimates for Alumis Lowered by Cantor FitzgeraldMarch 25, 2025 | americanbankingnews.comWhat is HC Wainwright's Estimate for Alumis Q1 Earnings?March 25, 2025 | americanbankingnews.comFY2025 EPS Estimates for Alumis Cut by Cantor FitzgeraldAlumis Inc. (NASDAQ:ALMS - Free Report) - Equities researchers at Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for shares of Alumis in a report released on Thursday, March 20th. Cantor Fitzgerald analyst E. Schmidt now anticipates that the company will post earningsMarch 24, 2025 | marketbeat.comHC Wainwright Issues Negative Forecast for Alumis EarningsAlumis Inc. (NASDAQ:ALMS - Free Report) - Research analysts at HC Wainwright dropped their Q1 2025 earnings per share (EPS) estimates for Alumis in a report issued on Thursday, March 20th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($1.29) per share forMarch 24, 2025 | marketbeat.comAlumis' (ALMS) "Overweight" Rating Reaffirmed at Cantor FitzgeraldCantor Fitzgerald reissued an "overweight" rating on shares of Alumis in a research report on Thursday.March 21, 2025 | marketbeat.comAlumis Inc. Reports Phase 2 and Phase 1 Clinical Data, Announces Merger Agreement with ACELYRIN, and Highlights 2024 Financial ResultsMarch 21, 2025 | nasdaq.comThursday’s 10 Worst-Performing StocksMarch 21, 2025 | insidermonkey.comAlumis (NASDAQ:ALMS) Earns "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $15.00 target price (down from $19.00) on shares of Alumis in a report on Thursday.March 21, 2025 | marketbeat.comAlumis Inc.: Alumis Reports Year End 2024 Financial Results and Highlights Recent AchievementsMarch 20, 2025 | finanznachrichten.deAlumis price target lowered to $15 from $19 at H.C. WainwrightMarch 20, 2025 | markets.businessinsider.comOppenheimer Sticks to Their Buy Rating for Alumis Inc. (ALMS)March 20, 2025 | markets.businessinsider.comAlumis Reports Year End 2024 Financial Results and Highlights Recent AchievementsMarch 19, 2025 | globenewswire.comAlumis Inc. (NASDAQ:ALMS) Receives Average Recommendation of "Buy" from BrokeragesAlumis Inc. (NASDAQ:ALMS - Get Free Report) has earned an average recommendation of "Buy" from the nine research firms that are presently covering the firm, Marketbeat.com reports. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the compMarch 16, 2025 | marketbeat.comAcelyrin adopts poison pill as Tang Capital Partners raises stakeMarch 13, 2025 | msn.comDrug developers Pliant and Acelyrin adopt poison pill provisions to fend off activist investorMarch 13, 2025 | bizjournals.comAlumis Inc. (ALMS) Receives a Buy from H.C. WainwrightMarch 11, 2025 | markets.businessinsider.comAlumis announces data from the OLE of its Phase 2 STRIDE trialMarch 10, 2025 | markets.businessinsider.comHow a skin drug trial could help Peninsula biotech pull off key mergerMarch 10, 2025 | bizjournals.comAlumis Inc. (ALMS) Receives a Buy from OppenheimerMarch 10, 2025 | markets.businessinsider.comAlumis' (ALMS) "Buy" Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and set a $19.00 target price on shares of Alumis in a research report on Monday.March 10, 2025 | marketbeat.comAlumis to Present at Leerink's 2025 Global Healthcare ConferenceMarch 10, 2025 | globenewswire.comPromising Efficacy of Alumis Inc.’s ESK-001 in Psoriasis Treatment Boosts Market Position and Buy RatingMarch 10, 2025 | tipranks.comLate-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in PsoriasisMarch 8, 2025 | globenewswire.comAlumis Inc. and ACELYRIN, Inc. Confirm Commitment to All-Stock Merger to Create Leading Biopharma Company in Immune-Mediated DiseasesMarch 4, 2025 | quiverquant.comACELYRIN, INC. and Alumis Inc. Announce Merger to Create Leading Clinical Stage Biopharma Company in Immune-Mediated DiseasesMarch 4, 2025 | quiverquant.comAlumis Inc. Announces Merger with ACELYRIN, Inc.March 4, 2025 | tipranks.comAlumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed MergerMarch 4, 2025 | globenewswire.comACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis MergerMarch 4, 2025 | globenewswire.comAlumis Inc. (ALMS) Gets a Buy from OppenheimerMarch 3, 2025 | markets.businessinsider.comAlumis' (ALMS) Buy Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and set a $19.00 target price on shares of Alumis in a report on Monday.March 3, 2025 | marketbeat.comAlumis Announces 52-Week Phase 2 Data For ESK-001 In Psoriasis At 2025 AAD MeetingMarch 2, 2025 | nasdaq.comAlumis to present new data on multiple sclerosis therapyMarch 1, 2025 | investing.comAlumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data ReadoutFebruary 28, 2025 | globenewswire.comAlumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative DiseasesFebruary 27, 2025 | globenewswire.comAlumis Inc. Approves New Severance and Control PlanFebruary 21, 2025 | tipranks.comACELYRIN shares surge on buyout interestFebruary 21, 2025 | in.investing.com Remove Ads Get Alumis News Delivered to You Automatically Sign up to receive the latest news and ratings for ALMS and its competitors with MarketBeat's FREE daily newsletter. Email Address ALMS Media Mentions By Week ALMS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALMS News Sentiment▼1.280.61▲Average Medical News Sentiment ALMS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALMS Articles This Week▼74▲ALMS Articles Average Week Remove Ads Get Alumis News Delivered to You Automatically Sign up to receive the latest news and ratings for ALMS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AUPH News ADPT News IOVA News ETNB News SNDX News MLYS News GPCR News SYRE News ELVN News COLL News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALMS) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredEU’s Action Takes Aim At US RetireesTrump's Return Sparks Massive Gold Rush—Is Your 401(k) Ready for the Fallout? With President Trump back and...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alumis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alumis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALMS Stock Free ALMS Stock Alerts